ARS Pharmaceuticals, Inc. (SPRY)
NASDAQ: SPRY · Real-Time Price · USD
17.92
-0.08 (-0.44%)
At close: Jul 24, 2025, 4:00 PM
17.60
-0.32 (-1.79%)
After-hours: Jul 24, 2025, 7:21 PM EDT
ARS Pharmaceuticals Employees
As of December 31, 2024, ARS Pharmaceuticals had 160 total employees, including 155 full-time and 5 part-time employees. The number of employees increased by 134 or 515.38% compared to the previous year.
Employees
160
Change (1Y)
134
Growth (1Y)
515.38%
Revenue / Employee
$607,013
Profits / Employee
-$97,813
Market Cap
1.76B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 160 | 134 | 515.38% |
| Dec 31, 2023 | 26 | 6 | 30.00% |
| Dec 31, 2022 | 20 | 11 | 122.22% |
| Dec 31, 2021 | 9 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
SPRY News
- 6 days ago - EURneffy® (adrenaline nasal spray) Approved in the U.K. as the First and Only Needle-Free Emergency Treatment of Allergic Reactions (anaphylaxis) - GlobeNewsWire
- 2 months ago - ARS Pharmaceuticals to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 2 months ago - ARS Pharmaceuticals, Inc. (SPRY) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 2 months ago - ARS Pharmaceuticals Reports First Quarter 2025 Financial Results and Highlights Progress in U.S. Commercial Launch of neffy® (epinephrine nasal spray) - GlobeNewsWire
- 2 months ago - ARS Pharmaceuticals' neffy® (epinephrine nasal spray) 1 mg is Now Available in the United States for Type I Allergic Reactions, including Anaphylaxis, in Pediatric Patients Weighing 15 to < 30 Kilograms - GlobeNewsWire
- 2 months ago - ARS Pharmaceuticals Announces Conference Call and Webcast for its First Quarter 2025 Financial Results - GlobeNewsWire
- 2 months ago - ARS Pharmaceuticals Announces Co-Promotion Agreement with Partner and Global Allergy Leader ALK-Abelló A/S to Expand Reach of neffy® (epinephrine nasal spray) to Additional U.S. Pediatricians - GlobeNewsWire
- 3 months ago - ARS Pharmaceuticals Has A Blockbuster Candidate - Seeking Alpha